Abstract

Meeting abstracts Our aim was to describe our experience with surgery after High-dose Interleukin-2 (HD IL-2) therapy in patients who were eligible for complete metastasectomy after treatment. A retrospective chart review was performed on patients with metastatic melanoma seen at Saint Louis

Highlights

  • Our aim was to describe our experience with surgery after High-dose Interleukin-2 (HD IL-2) therapy in patients who were eligible for complete metastasectomy after treatment

  • A retrospective chart review was performed on patients with metastatic melanoma seen at Saint Louis University from January 1999-June 2011 who were partial responders to HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses)

  • Survival estimates for patients that were able to undergo complete metastasectomy after HD IL-2 were compared to established expected duration of survival with systemic therapy alone from the MSLT-1 trial

Read more

Summary

Introduction

Our aim was to describe our experience with surgery after High-dose Interleukin-2 (HD IL-2) therapy in patients who were eligible for complete metastasectomy after treatment. Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma Background Our aim was to describe our experience with surgery after High-dose Interleukin-2 (HD IL-2) therapy in patients who were eligible for complete metastasectomy after treatment.

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Left Posterior Fascicular Block Due to High-Dose lnterleukin-2
Anand Singla ... Samuel R Denmeade
Annals of Pharmacotherapy | VOL. 42
Anand Singla, et. al.Anand Singla ... Samuel R Denmeade
29 Jul 2008
High-dose interleukin-2 therapy related adverse events and implications on imaging.
Neal R Shah ... Kianoush Ansari-Gilani
Diagnostic and Interventional Radiology | VOL. 27
Neal R Shah, et. al.Neal R Shah ... Kianoush Ansari-Gilani
20 Sep 2021
Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma
S F Powell ... A Z Dudek
Journal of Clinical Oncology | VOL. 27
S F Powell, et. al.S F Powell ... A Z Dudek
20 May 2009
Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma.
Melinda Bernabe Chu ... John M Richart
Journal of Clinical Oncology | VOL. 31
Melinda Bernabe Chu, et. al.Melinda Bernabe Chu ... John M Richart
20 May 2013
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma
Olaya De Dios ... Pilar Sánchez-Gómez
Journal for ImmunoTherapy of Cancer | VOL. 12
Olaya De Dios, et. al.Olaya De Dios ... Pilar Sánchez-Gómez
30 Aug 2024
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
Brenda C O'Connell ... Stephane Peluso
Journal for ImmunoTherapy of Cancer | VOL. 12
Brenda C O'Connell, et. al.Brenda C O'Connell ... Stephane Peluso
30 Aug 2024
Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy
Christoforos Vaxevanis ... Barbara Seliger
Journal for ImmunoTherapy of Cancer | VOL. 12
Christoforos Vaxevanis, et. al.Christoforos Vaxevanis ... Barbara Seliger
29 Aug 2024
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors
Fei Zhu ... Dafei Chai
Journal for ImmunoTherapy of Cancer | VOL. 12
Fei Zhu, et. al.Fei Zhu ... Dafei Chai
28 Aug 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.